USANA Health Sciences (NYSE: USNA) reported Q3 EPS of $0.56, $0.07 better than the analyst estimate of $0.49. Revenue for the quarter came in at $200.22 million versus the consensus estimate of $206.14 million.

GUIDANCE:

USANA Health Sciences sees FY2024 EPS of $2.40-$2.55, versus the consensus of $2.50. USANA Health Sciences sees FY2024 revenue of $850-880 million, versus the consensus of $861.9 million.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.